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Introduction
The presence of deep venous thrombosis involving the veins of the legs,
pelvis, and vena cava or axillary and subclavian veins is an emergency
situation, requiring immediate therapy. This presentation is confined to a
brief discussion of the clinical utilization of antithrombotic agents in the
management of this condition and its sequelae. Certain ancillary measures
which are an integral part of treatment of deep venous thrombosis (limb
elevation, elastic support) or pulmonary emoblism (respiratory support,
vasopressors, antiarrhythmic drugs, etc.) are well known and have been
discussed elsewhere.1
Heparin
Heparin has been the agent of choice for the initiation of therapy for
venous thromboembolism. The selective use of a thrombolytic agent will be
discussed in a subsequent section.
Recent pharmacologic studies have demonstrated that heparin is a heter-
ogeneous mixture of active and inactive fractions of a sulfated mucopolysac-
charide varying in molecular weight from 6,000-25,000; however, there is no
evidence that commercially available products differ in antithrombotic po-
tency if dosage is prescribed in heparin units. The anticoagulant effect of
heparin is dependent upon its &dquo;activation&dquo; of antithrombin III, an a-2
globulin present in normal plasma. Heparin acts to accelerate the rate of
From the Department of Surgery, University of Michigan Medical Center, 1405 East Ann Street,
Ann Arbor, Michigan 48109.
2
complexing of antithrombin with various serine proteases (thrombin and
factors IX, X, XI, XII), thus inhibiting the normal process of blood coagu-
lation. In patients with extensive intravascular thromboses, much larger than
usual doses of heparin are occasionally required to achieve a predetermined
level of anticoagulation; this may be related to the release of increased
amounts of an antiheparin factor from platelets (platelet factor 4) involved
in the thrombotic process.
The demonstration that the anticoagulant half-life of heparin in circulation
is less than 2 hours in normal subjects and patients with venous thrombosis
and even shorter in patients with pulmonary embolism has made continuous
IV infusion the preferred method of administration. In addition to maintain-
ing a more constant blood level of heparin, two recent prospective trials2, 
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comparing continuous infusion with intermittent IV injection have shown
that lesser amounts of heparin are needed with continuous infusion to
maintain an adequate degree of anticoagulation and that hemorrhagic com-
plications are appreciably less than with &dquo;pulse&dquo; injection.
When continuous infusion is utilized, direct IV injection of a loading dose
of 3000-6000 units of dilute aqueous heparin is given before the infusion is
started. A constant rate of infusion is maintained by use of an infusion pump.
If a pump is not available, a pediatric burette, filled with a specific volume of
heparin solution at hourly intervals, is a satisfactory alternative. In patients
with venous thrombosis alone, the initial rate of administration of heparin is
1200 units/hour; in patients with pulmonary embolism, 1700 units/hour are
infused. After approximately 3 anticoagulant half-lives (4-6 hours), the
circulating blood level should have stabilized and can be monitored with an
appropriate clotting test; the rate of infusion is adjusted if satisfactory
anticoagulation has not been obtained.
If continuous infusion of heparin is not feasible, intermittent IV injection
of dilute aqueous heparin (1000 units/ml) in a dose of 5000-6000 units every
4 hours is a satisfactory alternative which has been linked with a very low
frequency of recurrent thromboembolism during therapy.2 A heparin &dquo;well&dquo;
(a small-caliber, butterfly-type of needle connected by a plastic catheter to
a rubber diaphragm) can be utilized to lessen discomfort from repeated
injections; from a pharmacokinetic standpoint, injections every 2 hours would
be more desirable, but this doubles the workload of nursing staff. The total
daily dose of heparin is usually in the range of 30,000-40,000 units if this
method is used.
Although SC injection of aqueous concentrated heparin (20,000-40,000
units/ml) at 8-12-hour intervals has been utilized for many years for pro-
phylaxis and treatment of selected ambulatory patients, its comparative
efficacy in the management of acute venous thromboembolism has not been
assessed.
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Monitoring of the level of anticoagulation by one of several laboratory
tests is essential. Although the use of coagulation tests in patients receiving
intermittent IV injections of heparin may not lessen the frequency of hem-
orrhagic complications, there are data to show that maintenance of a given
level of anticoagulation (an increase in activated partial thromboplastin time,
thrombin clotting time, or Lee-White clotting time to 2-3 times normal) will
lessen the frequency of thromboembolic complications.
The most widely used tests for regulating heparin therapy are the activated
partial thromboplastin time (APTT) or the thrombin clotting time (TCT).
A common problem in the use of these tests is failure to properly standardize
the procedure by testing with varying concentrations of heparin in vitro.
This is particularly important when the APTT is used since the &dquo;partial
thromboplastin&dquo; reagents used in this test vary from laboratory to laboratory
and some reagents (e.g. ellagic acid) lessen the sensitivity of the test to
heparin. Monitoring of intermittent IV heparin therapy should be performed
about 1 hour before the next injection and is repeated at daily or more
frequent intervals to ensure that a cumulative increase in heparin level is not
present and also that dosage is adequate.
Bleeding during heparin therapy is more frequent in elderly patients,
particularly females, and in individuals with recent operations, ulcerative
lesions, or hemostatic abnormalities. Special caution should be taken to
ensure that that the subject is not receiving any drugs affecting platelet
function. A recent concern are reports of occasional heparin-induced throm-
bocytopenia. Controversy exists concerning the frequency of this complica-
tion. In our experience and that of others,4° a significant reduction in platelet
count is rare but, since this complication does occur, periodic platelet counts
are desirable.
Oral Anticoagulants
Treatment with oral anticoagulants should accompany and supplement
heparin therapy in all patients with major venous thromboembolism who
have no serious contraindications to such treatment, are cooperative, and
live in an area in which reliable laboratory control is available. Orally
administered anticoagulants (coumarin or indandione derivatives) antagonize
the action of vitamin K which is necessary for the y-carboxylation of glutamic
acid residues of the vitamin K-dependent clotting factors II, VII, IX, and X.
The result is the synthesis by the liver of dysfunctional forms of these
clotting factors which are no longer able to bind the calcium ions necessary
for subsequent phospholipid binding and clotting factor activation. This
effect is not immediate; effective anticoagulation occurs only after depletion
of circulating functional vitamin K-dependent clotting factors. The maximum
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depression of clotting factor activity occurs only after 5-7 days of adminis-
tration. Since the optimal antithrombotic effect is achieved only after this
interval, both heparin and oral anticoagulant administration should overlap
over a period of 1 week.
Although the clinical significance of several laboratory findings has not
yet been assessed, oral anticoagulant therapy should probably be initiated
during the first week of treatment with heparin. Several investigators6, have
reported that heparin therapy results in a progressive decrease in antithrom-
bin III. Since warfarin appears to sustain or elevate antithrombin III levels
in blood,8 the early administration of oral anticoagulant might prevent some
of the thrombotic complications observed after heparin therapy.’
While heparin therapy is maintained, the oral anticoagulant may be
administered daily in an anticipated maintenance dose (e.g. 10-15 mg of
warfarin); this avoids the occasional excessive anticoagulant effect observed
when larger loading doses are given. At the end of 1 week, the expected
therapeutic range of 20-30% prothrombin activity with the 1-stage prothrom-
bin time should be achieved. Since individual patients exhibit as much as 10-
fold variability in dosage requirements, daily laboratory monitoring is im-
portant until a stable maintenance dose has been determined.
Whenever feasible, oral anticoagulant treatment should be continued after
the patient is discharged from the hospital. The use of supplemental therapy
in ambulatory patients has been shown to reduce the frequency of recurrent
thromboembolic complications.’ The patient with a first episode of venous
thrombosis is treated for a period of 4-6 months. A longer period of therapy
may be desirable for the individual who has developed recurrent episodes.
Whether alternative prophylaxis with self-injection of low-dose heparin is
equally effective is still unresolved. 10, il
Major hemorrhage has complicated therapy in about 2% of hospitalized
patients, with minor bleeding in approximately 5%.12 Bleeding is somewhat
more frequent in ambulatory patients but is usually minor and manageable
solely by adjustment of the dose of oral anticoagulant. The use of vitamin K1
to reverse the anticoagulant effect is reserved for major episodes of hemor-
rhage, because patients frequently become more refractory to subsequent
administration of anticoagulant. All patients receiving oral anticoagulants
should be carefully evaluated for the intake of other drugs which may
interact with and influence anticoagulation;13 no interacting drug should be
introduced or withdrawn during oral anticoagulant therapy without careful
serial monitoring of changes in prothrombin activity.
Thrombolytic Agents
Since thrombolytic agents of adequate potency have been in clinical use
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for a much shorter period of time, definitive cost-benefit data are not yet
available. A recent consensus development conference sponsored by the
National Institutes of Health has justifiably advocated their more widespread
use in patients with major venous thromboembolism of recent origin,&dquo; but
much more information is required regarding the most appropriate agent or
combination of agents, dosage, duration of therapy, route of administration,
patient selection, and tests for monitoring effectiveness and hemorrhagic
tendency.
The 2 products currently approved by the Food and Drug Administration
are streptokinase, derived from cultures of ~3-hemolytic streptococci, and
urokinase, extracted from human fetal kidney cell cultures. Streptokinase
acts by formation of a plasminogen-streptokinase activator complex while
urokinase acts directly to convert plasminogen to the serine protease, plas-
min. The proteolytic enzyme, plasmin, produces fibrinolysis and, secondarily,
fibrinogenolysis. When these agents are administered IV, fresh thrombi or
pulmonary emboli may partially or completely lyse within 12-72 hours; the
longer period of treatment has been used more frequently in the treatment
of deep venous thrombosis, but the ideal duration of therapy is not yet
known.
Streptokinase is usually administered in a loading dose of 250,000 units
over 30 minutes followed by an infusion of 100,000 units/hour. Urokinase
has been given in a loading dose of 4400 units/kg of body weight followed by
hourly infusion of a similar dose. Both agents may produce a pyrogenic or an
allergic response; some investigators pretreat patients with hydrocortisone
to suppress allergic reactions. Prior to treatment, laboratory tests should
include hematocrit, platelet count, prothrombin time, APTT, and TCT; some
physicians would include measures of euglobulin lysis and fibrinogen. All of
these values should be within normal or acceptable limits before starting
therapy. A 2-fold or greater prolongation of TCT is evidence that a fibrino-
lytic state has been produced, but the magnitude of the prolongation appears
to have little or no value in predicting risk of bleeding or extent of thrombus
dissolution.15 If the thrombin time exceeds 5 times normal, the infusion is
terminated until a repeat determination reaches this limit. If serious bleeding
occurs, thrombolytic therapy should be discontinued and blood loss should
be replaced; since the half-life of these agents in the circulation is quite short,
the use of E-aminocaproic acid is seldom necessary. When massive bleeding
is present, a loading dose of 5 g of E-aminocaproic acid is given IV, followed
by 1 g/hour for the next 2-4 hours. To lessen the risk of bleeding during use
of these agents, all nonessential invasive procedures, including SC and
intramuscular injections, should be avoided and concomitant use of heparin
or antiplatelet agents should be prohibited. Two to four hours after termi-
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nation of the infusion, clotting studies are repeated and have usually returned
to values (TCT less than twice normal) which permit initiation of heparin
therapy. Since thrombolytic therapy is adjunctive in nature, it should be
followed by treatment with heparin and oral anticoagulants.
Unless very careful patient selection is used, bleeding complications will
be more frequent than with anticoagulant therapy. Major contraindications
to use of these agents include patients with uncorrected hemostatic defects,
cerebrovascular accident or other active intracranial diseases (within 2
months), recent operation or postpartum state or severe trauma (within 10
days), recent needle puncture of major vessels, organs, pleural or peritoneal
cavities, or subdural space. Other situations in which thrombolytic therapy
should not be utilized except after careful consideration of risk-benefit are
severe hypertension, pregnancy, advanced age, ulcerative lesions of the
gastrointestinal tract, bacterial endocarditis, major hepatic or renal disease,
and recent cardiopulmonary resuscitation.
Since both streptokinase and urokinase are expensive drugs, further studies
of cost effectiveness are necessary before definitive statements concerning
patient selection can be made. In the recent clinical trials of these agents in
the treatment of pulmonary embolism, although more rapid resolution of
emboli occurred during the first 5 days of therapy when thrombolytic drugs
plus heparin were compared with heparin therapy alone, there was no
difference in mortality between the 2 groups of subjects. If mortality alone
is considered, thrombolytic therapy may have a significant effect only in
patients with hemodynamically unstable, immediately life-endangering, mas-
sive pulmonary embolism. Whether there is a clinically important influence
of thrombolytic agents upon long-term morbidity from pulmonary embolism
is still equivocal. Similarly, although there are some suggestive data to
indicate that treatment of iliofemoral venous thrombosis with streptokinase
may achieve complete thrombolysis16 and lessen postphlebitic sequellae,17
further investigations are required to confirm these findings and to determine
whether certain subjects (e.g. those with isolated segmental femoral or iliac
veins thrombosis) are more likely to benefit than others. In the interim, in
the absence of any of the contraindications listed above, thrombolytic ther-
apy should be considered in patients with angiographically proven major
pulmonary embolism and in individuals with venographically documented
iliofemoral venous thrombosis.
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